Skip to main content
Oxford University Press - PMC COVID-19 Collection logoLink to Oxford University Press - PMC COVID-19 Collection
. 1996 May;173(5):1062–1071. doi: 10.1093/infdis/173.5.1062

Neutralization of Human Cytomegalovirus by Human CD13-Specific Antibodies

Terrence D Giugni 1,2,3,, Cecilia Söderberg 1,2,3, Debby J Ham 1,2,3, Robert M Bautista 1,2,3, Kjell-Olof Hedlund 1,2,3, Erna Moller 1,2,3, John A Zaia 1,2,3
PMCID: PMC7110010  PMID: 8627055

Abstract

The mechanisms of inhibition of cytomegalovirus (CMV) infection by human CD13 (aminopeptidase N)-specific antibodies were studied. These antibodies protect CD13-negative and -positive cells from CMV infection only if incubated with the virus inoculum, suggesting they bind to CMV virions. The association of a CD13-like molecule with virions was further supported by the transfer of CD13 immunoreactivity to the surface of CD13-negative cells upon binding of CMV; the binding of CD13-specific antibodies directly to the surface of CMV virions; and the presence of anti-CD13 immunoreactive bands, including one with mobility similar to that of native cellular CD13 on immunoblots of proteins of purified CMV particles. Importantly, CD13-specific antibodies neutralize CMV in urine of neonates with congenital CMV, indicating that the CD13-like molecule is associated with natural CMV and not acquired in vitro. These studies demonstrate that a CD13-like molecule is associated with CMV particles and may be important in CMV pathogenesis.


Articles from The Journal of Infectious Diseases are provided here courtesy of Oxford University Press

RESOURCES